| Literature DB >> 34930033 |
Amélie Lombes1,2, Rémy A Bonnin2,3, Frédéric Laurent4, Hélène Guet-Revillet5, Emmanuelle Bille6, Vincent Cattoir7, Marie-Sarah Fangous8, Cécile Le Brun9, Vincent Fihman10, Frédéric Janvier11, Marie-Pierre Otto11, Anais Potron12, Stéphane Corvec13, Louise Ruffier d'Epenoux13, Assaf Mizrahi14,15, Laurent Dortet1,2,3.
Abstract
In this multicentric study performed in 12 French hospitals, we reported that 26.9% (14/52) of the amoxicillin-clavulanate-resistant Proteus mirabilis isolates produced the OXA-23 carbapenemase. We found that an inhibition zone diameter of <11 mm around the amoxicillin-clavulanate disc was an accurate screening cutoff to detect these OXA-23 producers. We confirmed by whole-genome sequencing that these OXA-23-producers all belonged to the same lineage that has been demonstrated to disseminate OXA-23 or OXA-58 in P. mirabilis.Entities:
Keywords: Acinetobacter; OXA-23; Proteae; carbapenemase; epidemiology; infectious clones
Mesh:
Substances:
Year: 2021 PMID: 34930033 PMCID: PMC8846483 DOI: 10.1128/AAC.01983-21
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.938